| 國立交通大學 |
2014-12-08T15:38:19Z |
Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells
|
Liu, Huei-Fang; Hu, Huai-Chin; Chao, Jui-I |
| 國家衛生研究院 |
2017-12-16 |
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
|
Hsu, HH;Chen, MC;Baskaran, R;Lin, YM;Day, CH;Lin, YJ;Tu, CC;Padma, VV;Kuo, WW;Huang, CY |
| 亞洲大學 |
2017-12 |
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
|
Hs, Hsi-Hsien;Hsu, Hsi-Hsien;Ming-Cheng, Cheng C;Chen, Ming-Cheng;Rathinasamy;Baskaran, Rathinasamy;Lin, Yueh-Min;Cecilia, H. D;Day, Cecilia H.;Lin, Yi-Jiun;Chuan-Chou, T;Tu, Chuan-Chou;Viswanadha, Viswanadha V;Padma, Viswanadha Vijaya;Kuo, Wei-Wen;黃志揚;Huang, Chih-yang |
| 臺大學術典藏 |
2020-03-05T06:28:40Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Cheng A.-L.; Chang Y.-L.; Yeh K.-H.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liang J.-T.; Lin Y.-.; Liang Y.-H.; Tsai J.-H.; JAU-YU LIAU |
| 國立臺灣大學 |
2014 |
Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
|
Lin, Yu-Lin; Liang, Yi-Hsin; Tsai, Jia-Huei; Liau, Jau-Yu; Liang, Jin-Tung; Lin, Been-Ren; Hung, Ji-Shiang; Lin, Liang-In; Tseng, Li-Hui; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii; 梁逸歆; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 蔡佳惠; 洪基翔; 林本仁; 廖肇裕; 梁金銅 |
| 臺大學術典藏 |
2020-02-25T05:15:26Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Liau J.-Y.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-.; Liang Y.-H.; Tsai J.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:15Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:25Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liau J.-Y.; Liang J.-T.; Tsai J.-H.; Liang Y.-H.; Lin Y.-.; Lin Y.-.;Liang Y.-H.;Tsai J.-H.;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Yih-Leong Chang;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T07:31:48Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.;Liang Y.-H.;Jia-Huei Tsai;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Chang Y.-L.;Yeh K.-H.;Cheng A.-L.; Lin Y.-.; Liang Y.-H.; JIA-HUEI TSAI; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-07T02:46:38Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; YI-HSIN LIANG; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
